BILINSKY IGOR 4

What Happened
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), had 31,246 restricted stock units (RSUs) vest on March 5, 2026. The RSUs converted into 31,246 shares (acquired at $0.00 per share as typical for RSU vesting). To satisfy mandatory tax withholding, 16,628 of those shares were withheld by the issuer at an indicated value of $4.58 per share (withholding value ≈ $76,156), leaving Bilinsky with 14,618 shares net.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 6, 2026 (timely).
• Vesting/Conversion: 31,246 RSUs converted to common stock (transaction code M).
• Tax withholding: 16,628 shares withheld (transaction code F) at $4.58/share = $76,156 (not an open‑market sale).
• Net shares issued to insider: 14,618 shares (31,246 − 16,628).
• Footnotes: Each RSU equals one share; withheld shares are solely for tax obligations; remaining RSUs from the March 5, 2025 grant will vest in equal quarterly installments.

Context
This was a standard RSU vesting and net settlement (company withheld shares to cover taxes), not a cash sale on the open market. For retail investors, vesting/withholding transactions are routine compensation events and do not by themselves indicate buying or selling sentiment.